Only the possibility of increasing survival with better tumor localization and staging is probable with multiparametric MRI—and improved survival with MR imaging in prostate cancer has not been shown in a clinical trial or meta-analysis to date.
To insure standardization of all aspects of care during the conduct of a clinical trial, clinical trials should include guideline-based criteria for the management of all symptoms of cancer and its treatment, and failure to adhere to any of the standards for symptom management during the conduct of the trial should result in an equal level of protocol violation.
This will have a significant impact on medicine and on the care we will be able to deliver. It has life and death implications. The patients of America, who have enjoyed the best healthcare in the world, have lost.
While ONCOLOGY has continued to evolve along with the field of oncology—for example, it now addresses critical issues of science and socioeconomics—it has remained true to the founding principles. Perhaps largely for this reason, the journal continues to be widely read across the entire oncology community.
The continuing challenge for every specialty in oncology is to improve the therapeutic ratio, which is the balance of the biological effectiveness of the treatment and the severity of treatment-related side effects.
This special supplement to Oncology News International comprises expert
commentary and selected reports from the 2004 meetings of RSNA and
ASTRO about new imaging techniques, with a focus on state-of-the-art magnetic
resonance imaging, positron emission tomography, computed tomography,
and complementary modalities for improving the diagnosis, staging, and
treatment of a variety of cancers. Evident in these reports is the increasing
collaboration between the specialties of radiation oncology and diagnostic
radiology as imaging technology continues to evolve.